Company intelligence / Profile preview

CapeHaven

New York, New York, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

CapeHaven is a venture-backed biotechnology company focused on the discovery and development of novel therapeutics for neurodegenerative and neuropsychiatric diseases. Incubated by Apple Tree Partners (ATP), the company is led by prominent neuroscience drug hunter Dr. Michael Ehlers. CapeHaven utilizes a proprietary platform to identify and modulate key biological pathways involved in brain health and disease. The company's pipeline is currently in the pre-clinical stage, targeting high-value indications with significant unmet medical needs. CapeHaven operates primarily in stealth mode, advancing small molecule candidates designed to address complex brain disorders.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on CapeHaven.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CapeHaven.

Explore the full profile